DCC-2036(rebastinib)isanAblinhibitorthatexhibitsanticanceractivity.Incellularmodelsofchronicmyelogenousleukemia(CML),rebastinibinducesapoptosisandinhibitscellproliferation.RebastinibbindstheswitchcontrolpocketofAblthatisinvolvedinconformationalregulationofthekinasedomain.
| CasNo. | 1020172-07-9 |
|---|---|
| Purity | ≥98% |
| Formula | C30H28FN7O3 |
| FormulaWt. | 553.59 |
| Synonym | DCC2036,Rebastinib |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | D0808InfoSheetPDF |
|---|
ShenY,ShiX,PanJ.TheconformationalcontrolinhibitoroftyrosinekinasesDCC-2036iseffectiveforimatinib-resistantcellsexpressingT674IFIP1L1-PDGFRα.PLoSOne.2013Aug29;8(8):e73059.PMID:24009732.
EideCA,AdrianLT,TynerJW,etal.TheABLswitchcontrolinhibitorDCC-2036isactiveagainstthechronicmyeloidleukemiamutantBCR-ABLT315Iandexhibitsanarrowresistanceprofile.CancerRes.2011May1;71(9):3189-95.PMID:21505103.
